Search Results (1073)

More Search Options
MatchTypeWhy
Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs.Academic Article Why?
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.Academic Article Why?
Genetic Modifiers such as Fas Regulate Tumor-Cell Dependence on Mutant EGFRGrant Why?
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.Academic Article Why?
EGFR-driven lung adenocarcinomas coopt alveolar macrophage metabolism and function to support EGFR signaling and growth.Academic Article Why?
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer TreatmentGrant Why?
Overcoming Resistance to Anti-EGFR Therapy by Drug RepurposingGrant Why?
Targeting the Urokinase Receptor in Glioblastoma MultiformeGrant Why?
AXL activates YAP through the EGFR-LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma.Academic Article Why?
Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.Academic Article Why?
Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.Academic Article Why?
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.Academic Article Why?
Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells.Academic Article Why?
Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B).Academic Article Why?
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.Academic Article Why?
Per Page    Page  of 72 Next
Prev
With one click, see people who:

Mentor Faculty

Run Clinical Trials

Work in Global Health Equity

Offer Student Projects

See more options in the Advanced Search tab

Search Criteria
  • EGFR
Search Result Filters
_
Click "Why?" to see why an item matched the search.

UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04.

Copyright © The Regents of the University of California.